Hope starts here.

2011

ANNUAL REPORT

Freedom from Infectious Disease

LETTER FROM THE PRESIDENT Seattle BioMed was founded 35 years ago with the vision of providing solutions to global infectious diseases through research. This vision gives hope for those who have no voice and no way to lift themselves out of the suffering caused by these diseases. It also lays the foundation for a healthier world that benefits all of us. Today we are fully committed and more able than ever to deliver on our vision. We know that research provides the foundation for the solutions that are needed to combat the worlds deadliest diseases. Global infectious diseases do not respect borders, which is increasingly the case as global travel and international business expand. The suffering and death that these diseases cause impacts each of us indirectly in many ways no matter where we live. The need for new solutions is greater than ever, but the good news is that we are making progress. Throughout this annual report, youll see how we are moving forward in making our vision a reality through our research. Youll read about new research projects, exciting discoveries and the people who are engaged in our mission, from students and researchers to donors and volunteers. We are excited about our future. By integrating the platform of systems biology with our infectious disease research, we are yet again pioneering the way in global health. The addition of new expertise, technologies and research programs has expanded our ability to have interdisciplinary scientific teams exploring the interface between pathogens and the humans that they infect. We can more deeply understand the biological mechanisms and processes at the level of complexity that occurs in biological systems. This enables us to gain new knowledge at a faster rate by taking a more systematic and comprehensive approach. Most importantly, I believe this integration of systems biology and infectious disease research will speed new solutions to those who need it most. We are most fortunate to have been joined by Alan Aderem, Ph.D., and many other scientists and staff this year. I welcome and support Alans move into the role of President of Seattle BioMed at the beginning of 2012. I look forward as President Emeritus and Founder to more fully focus on research projects and share the knowledge Ive gained from years of challenges and success in the burgeoning field of global health. I cant think of a more exciting and stimulating future here at Seattle BioMed than being surrounded by some of the brightest and most compassionate people in the world. We thank all of those who have assisted Seattle BioMed. We cannot accomplish our mission and provide hope without your help.

Ken Stuart, Ph.D. President & Founder

We believe hope starts with research. Seattle BioMeds 2011 Annual Report takes a look at research that is pushing discovery forward. Throughout these stories, we also glimpse forward to what the fruits of our science will bear healthy people and thriving communities.

LETTER FROM THE BOARD CHAIR

At various points in time, were provided the opportunity to celebrate both the past and the future at virtually the same moment. In 2011, Seattle BioMed had such an opportunity. We celebrated our 35th anniversary and 35 years of leadership by President and Founder Ken Stuart, Ph.D., a man who nurtured his vision into to a world-class center for infectious disease research the first global health organization in a city whose name has become synonymous with improving the health of the world. To view a retrospective of Seattle BioMeds history and understand how Kens vision has unfolded, please take a moment and visit seattlebiomed.org/history. At the same time, a bold plan for scientific expansion and leadership for the future came to fruition. To enhance our research, particularly in the last couple years, we added various areas of expertise (such as immunology, early clinical and regulatory development) through strategic

recruitment and expansion. We also began to explore the concept of applying a systems biology approach to infectious disease research, a truly revolutionary platform that has the potential to cut across and benefit all of our research programs. Through a series of discussions with Alan Aderem, Ph.D., co-founder of the Institute for Systems Biology, the idea took shape. It was soon evident that Alan a pioneer in the same vein as Ken was the right choice to further expand our research and eventually succeed Ken as only the second president in the history of Seattle BioMed. As a native of South Africa, Alan has long been interested in global health, has seen firsthand the devastation of infectious diseases, and believes Seattle BioMed is the perfect place to meld his personal and professional goals. From an organizational standpoint, Seattle BioMed will be incredibly fortunate as this transition occurs in January. Not only are we gaining Alan as President

to lead our efforts to integrate systems biology with infectious disease research, but we are retaining Ken in a new role as President Emeritus and Founder. We are so privileged to have two internationally renowned scientists in their respective fields in key roles at Seattle BioMed as we shape the next 35 years. Imagine what the world can be with new drugs and vaccines to combat infectious diseases healthy, productive and full of hope. Thank you for your support of Seattle BioMed.

Todd Patrick Chair, Board of Trustees

Predictive power: revolutionizing malaria vaccine discovery

After Seattle BioMed announced its bold plan to integrate a systems biology approach with its infectious disease research, malaria researchers wasted no time in incorporating this new method. In the first study of its type in the malaria field, Seattle BioMed researchers are identifying biomarkers that will allow malaria vaccine design based on robust predictors of protective immunity. The ability to predict is a hallmark of the systems biology approach. With an $8.9 million grant from the Bill & Melinda Gates Foundation, Seattle BioMeds Ruobing Wang, M.D., Ph.D., is leading the study with a team that includes Seattle BioMeds Stefan Kappe, Ph.D., and Alan Aderem, Ph.D., along with Patrick Duffy, M.D., of the National Institutes of Health, Jonathan Derry, Ph.D., of Sage Bionetworks, and Xiaowu Liang, Ph.D., of Antigen Discovery Inc. (ADi). In August 2011, the project was touted by a scientific website as one of 21 scientific research projects starting this fall that could change the world, citing the need for an effective vaccine to combat malaria. To conduct this research, Seattle BioMed is calling upon its proven areas of expertise and knowledge successful vaccine and immunology studies in animal models of malaria, the ability to grow human malaria parasites in mosquitoes for research and clinical studies, and its ability to develop genetically attenuated parasite strains for human trials. Researchers at Seattle BioMed will then apply the knowledge gained in mouse models to human studies. Through studies conducted at Seattle BioMeds Malaria Clinical Trials Center, well evaluate whether biomarkers of protection identified in the rodent models will predict protective immunity in humans, explained Wang. biological system. If we have the ability to predict whether a vaccine candidate for malaria will work before it goes into large scale clinical trials, we could move away from todays typical trial and error method toward a more powerful predictive approach to vaccine discovery and development, he said. Through these integrated studies, Seattle BioMed researchers will deliver a set of candidate immune biomarkers associated with protection against malaria infection that can be used for monitoring vaccine efficacy. This will facilitate future malaria vaccine trials with the ultimate goal of accelerating the development of a highly effective malaria vaccine that has the potential to save millions of lives, said Wang.

Fast track to vaccines

Applying Aderems expertise in the field of systems biology to malaria research will be a key component of this project. Seattle BioMed researchers are employing network analysis of transcriptional responses to predict protection in both mice and humans to determine if they can find universal markers that will allow them to optimize vaccine candidates. According to Aderem, the power of systems biology lies in its capacity to predict the behavior of a

From mice to men (and women)

Through Kappes research, Seattle BioMed scientists have developed genetically attenuated whole parasite (GAP) vaccine strains that have proven successful in rodent malaria models and have moved into human studies, which show the validity of the approach. In this new study, we will use genetically attenuated parasite strains as probes to determine whether host correlates of immunity can be identified during vaccination in mice, Kappe explained. These model vaccines provide an opportunity to discriminate biomarkers associated with complete, long-lasting protection from those associated with partial, short-lived or lack of protection.

Biomarkers key to vaccines

According to Wang, the goal of the study is to identify and validate biomarkers that correlate with vaccine-induced protective immunity against malaria infection. In order to bring the burden of malaria under control with the ultimate goal of eradicating the pathogens that cause disease we know we need a highly efficacious antiinfection vaccine, she explained. But, without reliable biomarkers of anti-infection immunity, the development and testing of malaria vaccines is a slow and expensive process. Biomarkers will be used for prediction and monitoring the vaccine efficacy in clinical trials and to select optimal vaccine candidates for development.

One could never understand the complexity of the Amazon by investigating a single tributary. Instead, study how the river interacts with the environment throughout the basin. Then, one starts to understand the networks and relationships that make an ecosystem thrive. Systems biologists apply the same principles to study how disease impacts complex systems.
3

Ruobing Wang, M.D., Ph.D., Alan Aderem, Ph.D., and Stefan Kappe, Ph.D.

A critical piece of the HIV puzzle:

Helen Horton, Ph.D., stands at the white board in her office. Her face lights up as she draws an illustration to explain her latest research findings reflecting the excitement of scientific discovery. Many times people assume that research ends in a eureka finding resulting in a full-blown solution, but more often research builds upon itself, filling in yet another small piece of the disease puzzle. And each step in that discovery process provides new hope. A principal investigator at Seattle BioMed, Horton discovered a critical piece of information that adds new knowledge about HIV/AIDS, with far-reaching implications for both control of chronic infection and autoimmunity. Her findings were reported in the prestigious scientific journal Nature Medicine. Like many of her Seattle BioMed colleagues, Horton is motivated by two related objectives her natural curiosity of how biological systems work and her belief that research provides the basis for much-needed solutions for deadly infectious diseases. After completing her postdoctoral studies, she spent time traveling in Africa seeing first-hand the need to stop the deadly epidemic that was sweeping the continent. I realized that researching HIV/AIDS was the most important contribution I could make, she said.

solved
Her findings in Nature Medicine detail a previously unknown explanation for why long-term nonprogressors can control HIV infection. The new information Horton discovered proves to be beneficial in chronic infections, like HIV, but detrimental in autoimmunity. While weve learned a valuable piece of information we didnt know before, this leads to more questions, which will be the next focus of my research, said Horton.

And, shes found another piece of the HIV/AIDS puzzle. As Horton draws on her white board, she explains that, for many years, HIV/AIDS researchers have known that a group of rare individuals infected with HIV called long-term nonprogressors are able to control the virus without antiretroviral therapy (these individuals either do not develop full-blown AIDS or take much longer to develop the disease), but the specific method of how that happens wasnt known.

More than 33 million people are living with HIV/ AIDS worldwide. Researchers in Helen Hortons Seattle BioMed lab hope that understanding why some HIV-infected individuals never progress to AIDS could lead to an effective vaccine.
5

Helen Horton, Ph.D.

Natural selection:
finding future scientists and drug discoveries in our own backyard

When it comes to treating ailments, some of the best medicines are found in nature: White willow bark contains a chemical similar to aspirin. Quinine one of the first effective malaria treatments occurs in the bark of the cinchona tree. With drug resistance becoming more prevalent today, scientists are desperate to find new drugs to treat disease. Perhaps its only natural to turn an eye toward what grows in our own backyard. Jessica Winkler did just that. A 2006 graduate of Seattle BioMeds high school science education program BioQuest, Winkler is now continuing her training as an undergraduate intern in the tuberculosis research lab of David Sherman, Ph.D. She spent her summer paying forward the training she received by helping a local science teacher design an experiment that investigates the drug properties of Northwest plants.

A surprising discovery
Winkler tested various plant extracts moss, blackberry vine, even tomato leaf for their ability to inhibit growth of three different bacterial species: E.coli, Bacillus megaterium (found in soil) and Mycobacterium smegmatis (a non-pathogenic cousin of tuberculosis). My hypothesis was that one of the plant extracts would have some effect on inhibiting E.coli or B. megaterium growth, but probably not M. smegmatis. Her results yielded a surprising discovery: The moss sample significantly inhibited the growth of M. smegamtis. Winkler explained that, similar to M. tuberculosis (the bacteria that causes TB), M. smegmatis has a waxy, lipid-rich cell wall that creates a tough barrier for drugs to permeate. When her moss extract succeeded in inhibiting bacteria growth, researchers in Seattle BioMeds tuberculosis labs and BioQuest program took interest. Shermans lab hopes to reproduce these results and to test the moss sample on actual tuberculosis bacteria. Additionally, the BioQuest team is adding the moss extract to its tuberculosis latency experiments, where teens investigate TB-like bacterial responses to stress conditions involving low oxygen, changes in pH, starvation, and now the moss extract. My backyard moss wont be the silver bullet that stops TB, admits Winkler, but this experience has given me a great deal of hope for discoveries that can be made when students, teachers and scientists work together and learn from each other.

Student becomes teacher

I had the opportunity to help Lindberg High School teacher Anna Dehn develop a research experiment that could be replicated and taught in her classroom setting, said Winkler. I knew the class would need access to common materials, and with so many plants having antimicrobial and antibiotic properties, I thought: Why not use them in a drug discovery experiment? With a little guidance from her lab mentor Tracey Day, Ph.D., and with plenty of her own innovation, Winkler developed an engaging drug discovery lab that will be replicated for dozens of students in Dehns classroom. The BioQuest program helped me land a research job, so its exciting to think that my training led to a new lab that will engage more students in science, Winkler said.

Jessica Winkler

Training and education are inherent values of Seattle BioMed. Visit seattlebiomed.org and seattlebioquest.org to learn more about our training programs ranging from high school students to postdoctoral fellows.

Investigating infant immunity

In sub-Saharan Africa, more than 300,000 babies with HIV die each year. Mother-to-child transmission of HIV is as high as 40 percent, and HIV-infected children develop AIDS and die faster in South Africa than those in developed countries. For Heather Jaspan, Ph.D., a Seattle BioMed staff scientist who trained in the HIV lab of Don Sodora, Ph.D., and who also holds a research position at the University of Cape Town, the drive to better understand HIV transmission and disease progression bridges from professional to personal. I grew up in South Africa near Soweto, a community very much like Khayelitsha where I work with an HIV clinic, said Jaspan. I also have an 11-month-old son of my own. Hes full of energy and smiles, but I know many mothers and children in South Africa are battling the HIV burden. Jaspan believes she has an important role to play in helping the Khayeltisha community achieve better health. Thanks to grants awarded from the Pediatric AIDS Foundation and others, Jaspan spent the last year investigating whether or not a vaccination against an entirely different disease is increasing the probability that HIV-exposed infants contract HIV and more quickly progress to AIDS. immune responses to vaccines and infections and increased rates of disease progression in those infants that become HIV-infected, said Jaspan. During her summer internship made possible by Seattle BioMed donors who invest in scientific training Azenkot helped Jaspan test her hypothesis. We assessed immune cells in infants from South Africa clinics to determine the impact of the timing of BCG vaccination on immune responses to TB and other vaccines, explained Azenkot. Jaspan knows their test results will provide key insights into the effect of BCG vaccination on HIV disease susceptibility and progression. Results will also inform the optimal timing of BCG vaccination for HIV-exposed infants, she said. I hope our research will help us better understand whether or not to give HIV-exposed infants the BCG vaccine. And if so, when, Jaspan said. Ultimately, a better TB vaccine and an effective HIV vaccine are needed. Heather Jaspan, Ph.D., with her son in South Africa.

The TB vaccine dilemma

Bacille Calmette-Guern (BCG) vaccine is given to infants at birth in South Africa to protect them from severe forms of tuberculosis. While the BCG vaccination prevents healthy infants from getting sick from TB, it can also result in disseminated TB in HIV-positive infants and increase the risk of HIV infection among HIV-exposed infants. BCG is known to cause immune cells to be active and replicate faster, and infant immune systems respond differently to BCG than to other vaccines and infections. With a team of researchers including undergraduate Global Health Intern Tali Azenkot, Jaspan set out to examine the effect of BCG vaccination on HIV-exposed infants. We hypothesized that the routine immunization of infants with BCG contributes to generalized immune activation in HIV-exposed infants, resulting in skewed

Invest in innovation
Seattle BioMed donors who support research and scientific training have enabled dozens of students and scientists to get the training and funding they need to pursue innovative research ideas like Jaspans. Learn how you can help fund these projects, as well as help other scientists launch cutting-edge research aimed at tackling the toughest global health issues. Visit seattlebiomed.org/breakthrough-fund.

Don Sodora, Ph.D., and members of his lab greet a mother and daughter at a clinic in South Africa.

10

Hope among women

Two talented business women have been incredibly generous in dedicating their time and energy to advancing Seattle BioMeds mission especially as it relates to womens health. Members of the Board of Trustees Jane Hedreen, owner of childrens clothier Flora and Henri, and Kris Richey, vice president at Kinzer Real Estate Services, share their unique perspectives on why theyre champions for improved womens health. How can women improve global health?
At a networking event held specifically for women, a conversation sparked about some of the worlds toughest economic and social problems facing women and children today. I was struck by how little global health came into the conversation it seemed that people were clued into the ramifications of poor health, but they werent really seeing infectious disease as a root cause. Fortunately, that event was organized by Seattle BioMed as an opportunity to get women talking about the biggest barrier to global health infectious disease. A diverse, energized group of women started making connections between infectious diseases and the declining health of women and children around the world, and began asking what they could do to make improvements. Im excited to help Seattle BioMed continue outreach to women who are motivated to raise awareness of the challenges facing womens health and support for the hope offered by Seattle BioMeds research.

Did you know?

Womens traditional roles as the caretakers and brokers of health for their families put them at an unfair risk of contracting infectious diseases. Women with HIV may soon outnumber men with the disease. Pregnancy reduces a womans immunity to malaria, making her more vulnerable to illness, severe anemia and death. Tuberculosis is the third leading cause of death worldwide among women age 15-44 and the fourth leading cause of death of girls and young women in low-income countries. Scientists at Seattle BioMed are discovering new preventions and treatments against HIV/AIDS, malaria, TB and other diseases that are particularly dangerous to women.

Jane Hedreen
What inspires you to elevate global health awareness?
Years ago I heard economist Jeffrey Sachs speak at Seattle BioMeds annual fundraising event, Passport to Global Health Celebration. He was rattling off alarming statistics about the U.S. spending more money per day on the Pentagon than it spends in a year on global health. At that moment I knew that we, as an educated community, had an opportunity to shift that focus for the better. We needed to start acting on the burden of HIV/AIDS, malaria and TB diseases that have a detrimental impact on the world economy in the same way we act on other economic issues.

In many ways, Seattle BioMeds mission is close to that of my own business. Whether by encouraging women within my own network to learn about global health, or by raising awareness for the women in our factory in Madagascar, I like to think Im playing a small role in empowering women locally and globally to lead productive lifestyles for the betterment of themselves, their families and their communities.

Why is womens health global health?

I remember Melinda Gates saying that no mother in Africa should have to choose which of her children gets to sleep under a bed net. I agree that is a choice no mother should have to make. As smart, passionate women, we can build a global health community in the most positive sense one in which people from all social and economic backgrounds can come together to make a difference in the lives of others.

What connects you to Seattle BioMeds mission?

At my business Flora and Henri, we look to make connections with communities where we can make a lasting difference in the lives of women and children. We have made a commitment to partner with positive impact manufacturers to benefit women and children in developing areas, while teaching trades and supporting a womans ability to garner an independent wage.

Kris Richey
When did you discover your passion for improving global health?
My passion for global health goes back to my college days when I studied science and my early career as a scientist in the biotech industry. I eventually moved into the real estate business, and in 2005 I was introduced to Seattle BioMed via a real estate project. I was intrigued by the Institutes mission to end the threat of infectious disease, so it didnt take me long to ask Seattle BioMed how I could be of help. Six years later, Im on Seattle BioMeds board and helping the organization raise awareness of global health and infectious disease research.

Interested in learning more about ways infectious diseases impact womens health? Visit seattlebiomed.org and sign up to receive our global health newsletters and to attend events.

Learn more about the journeys of women who work at or support Seattle BioMed because they believe that womens health is global health. Hear their hopeful stories at seattlebiomed.org/breakthrough-fund.

Seattle BioMed Board Members Kris Richey (left) and Jane Hedreen.
11 12

Collaborators
INTERNATIONAL
Animal Health and Veterinary Laboratories Agency, United Kingdom Astellas Pharma Inc., Japan Australian National University, Canberra Biomedical Primate Research Centre, The Netherlands Centre Hospitalier Universitaire Vaudois, Lausanne Christian de Duve Institute of Cellular Pathology, Universit Catholique de Louvain, Belgium Egerton University, Kenya ETH-Zurich (Swiss Federal Institute of Technology Zurich) Griffith University, Australia Guys Hospital, United Kingdom Foundation for Innovative New Diagnostics, Switzerland Imperial College, London INOVIO, Norway Institute of Infectious Diseases and Molecular Medicine, University of Cape Town Institute of Parasitology, Czech Academy of Sciences, Czech Republic Institut Pasteur, France Institut Pasteur, Korea Institute of Protein Biochemistry, National Research Council, Italy International AIDS Vaccine Initiative International Center for Genetics and Biotechnology, India International Centre for Diarrheal Disease Research, Bangladesh Jawaharlal Nehru University, India K-RITH (KwaZulu-Natal Research Institute for Tuberculosis and HIV) London School of Hygiene and Tropical Medicine, United Kingdom Mahidol University, Bangkok, Thailand McGill University, Canada Melbourne University Morogoro Regional Hospital, Tanzania Nanomics Biosystems Pty Ltd, Australia National Institute of Infectious Diseases, Japan National Institute for Medical Research, London National Institute for Medical Research, Tanzania National Institute of Public Health and the Environment, The Netherlands National Research Council of Canada Novartis Institute of Tropical Diseases, Singapore Oxford University, United Kingdom

UNITED STATES
Aaron Diamond AIDS Research Center Antigen Discovery, Inc. AttoDX, Inc. Bill & Melinda Gates Foundation Boston University Brandeis University Broad Institute Brown University Medical School Buck Institute C3 Jian, Inc., Los Angeles California Institute for Medical Research California Institute of Technology California National Primate Research Center Centers for Disease Control & Prevention Columbia University Cornell University Drexel University Duke University Emory University Fred Hutchinson Cancer Research Center General Hospital Corporation (Massachusetts General Hospital) Harborview Medical Center Harvard University Indiana University Infectious Disease Research Institute Institute for Systems Biology Johns Hopkins University Keck Graduate Institute La Jolla Institute of Allergy and Immunology Los Alamos National Laboratory Microsoft Research National Institute on Alcohol Abuse and Alcoholism Intramural Program National Institutes of Health New York University North Carolina State University Northwestern University Novartis Vaccines & Diagnostics Oregon Health & Science University Oregon National Primate Research Center Oregon State University PATH Pacific Northwest National Laboratory Portland Veterans Affairs Medical Center Quality Biological, Inc.

Response Biomedical Corporation, Canada Ruhr-Universitt Bochum, Germany Sokoine University, Tanzania Swiss Tropical and Public Health Institute TriTryp Genome Consortium Tumaini University, Tanzania Unversidade Federal de So Paulo, Escola Paulista de Medicina, Brazil Universittsklinikum Charit Berlin, Germany University Hospitals Geneva, Switzerland University of Alberta University of Amsterdam University of Antioquia, Colombia University of Buea, Cameroon University of Cambridge, United Kingdom University of Cape Town, South Africa University of Copenhagen and Rigshospitalet, Denmark University of Dar es Salaam, Tanzania University of Dundee, Scotland University of Edinburgh, Scotland University of Glasgow, Scotland University of Heidelberg, Germany University of Nairobi, Kenya University of Osaka, Japan

University of Otago, New Zealand University of Queensland, Australia University of the Ryukyus, Japan University of Strausbourg, Germany University of the Witwatersrand, Johannesburg, South Africa University of Tokyo, Japan Vrije Universiteit, The Netherlands Walter and Eliza Hall Institute of Medical Research, Australia Wellcome Trust Sanger Institute, United Kingdom

Rockefeller University Saint Louis University Santa Clara Valley Medical Center Schering Plough Biopharma Scripps Research Institute Seattle Childrens Hospital Seattle Genetics Southwest National Primate Research Center, San Antonio St. Judes Childrens Hospital, Memphis Stanford University TB Control Program, Public Health Seattle-King County Texas A & M University Tulane National Primate Research Center Tulane University University of California, Berkeley University of California, Davis University of California, Los Angeles University of California, San Francisco University of Chicago University of Illinois, Chicago University of Iowa University of Maryland University of Massachusetts, Worchester University of Medicine and Dentistry of New Jersey University of Michigan

University of Missouri University of Nebraska University of North Carolina University of Oklahoma University of Oregon University of Pennsylvania University of Pittsburgh University of Rochester Medical Center University of San Diego University of Texas Health Science Center at San Antonio University of Texas Southwestern Medical Center at Dallas University of Virginia University of Washington U.S. Environmental Protection Agency Vanderbilt University J. Craig Ventner Institute Walter Reed Army Institute of Research Washington National Primate Research Center Yale University Yecuris Corporation Yerkes National Primate Research Center, Atlanta

GRANTORS & CONTRACTORS

Bill & Melinda Gates Foundation Burroughs Wellcome Fund Foundation for the National Institutes of Health Fred Hutchinson Cancer Research Center Implicit Bioscience Ltd. Infectious Disease Research Institute Institute for Systems Biology National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development Fogarty International Center National Center for Research Resources National Heart, Lung, and Blood Institute National Institute of Allergy and Infectious Diseases National Institute of Dental and Craniofacial Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute of General Medical Sciences New York University Oregon Health and Science University PATH Paul G. Allen Family Foundation Rhode Island Hospital Rockefeller University Science Applications International Corporation The Scripps Research Institute Sequella, Inc. Silver Family Foundation Stanford University U.S. Army Medical Research and Materiel Command U.S. Department of Health and Human Services HRSA United States-Israel Binational Science Foundation University of Cape Town University of Pennsylvania University of Washington

13

14

SEATTLE BIOMED LEADERS

PRINCIPAL INVESTIGATORS
Alan Aderem, Ph.D. Institute Director* John Aitchison, Ph.D. Full Member & Director Integrative Biology Jerry Cangelosi, Ph.D. Affiliate Member Nick Crispe, M.D., Ph.D. Full Member Malcolm Gardner, Ph.D. Full Member Christoph Grundner, Ph.D. Assistant Member Helen Horton, Ph.D. Associate Member Stefan Kappe, Ph.D. Full Member & Program Director Peter Myler, Ph.D. Full Member Marilyn Parsons, Ph.D. Full Member & Program Director David Sherman, Ph.D. Full Member & Program Director Joe Smith, Ph.D. Associate Member Don Sodora, Ph.D. Associate Member Leo Stamatatos, Ph.D. Full Member & Program Director Ken Stuart, Ph.D. Full Member, President & Founder** Kevin Urdahl, M.D., Ph.D. Assistant Member Ruobing Wang, M.D., Ph.D. Associate Member Theodore White, Ph.D. Full Member

PRINCIPAL SCIENTISTS
Sean Gray, Ph.D. Andrew Oleinikov, Ph.D. Noah Sather, Ph.D.

CLINICAL TRIALS INVESTIGATORS

Sara Healy, M.D., Clinical Trial Investigator Angela Talley, M.D., Lead Trials Investigator

COUNCIL OF SCIENTIFIC ADVISORS

Rafi Ahmed, Ph.D. Director, Emory Vaccine Center Clifton E. Barry, III, Ph.D. Senior Investigator, Chief, Tuberculosis Research Section, NIAID, NIH Bennett (Ben) M. Shapiro, M.D. Chair Director of Research, Retired, Merck Research Laboratories Jeffrey V. Ravetch, M.D., Ph.D. Theresa and Eugene Lang Professor at the Rockefeller University; Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology John W. Shiver, Ph.D. Vice President, Worldwide Basic Research Franchise; Head, Vaccines, Merck Research Laboratories Mike Tyers, Ph.D. CH Waddington Chair in Systems Biology, University of Edinburgh; Director of Scottish Universities Life Sciences Alliance (SULSA) Thomas E. Wellems, M.D., Ph.D. Chief, Malaria Genetics Section, NIAID, NIH

EMERITUS BOARD
Alan Alhadeff Margaret Allen, M.D. Ellsworth Alvord, Jr, M.D. Mark Benjamin, Sc.D. J Paul Blake Carol Bryan Vince Bryan Robert Bunting Alice Burgess John Creighton, Esq. Andrew Dale James Davie Nancy Duncan Bruce Easter Janet Lane Eaton Steve Gillis, Ph.D. Harris Hoffman James A. Johnson John King Alvin Kwiram, Ph.D. Carol Lewis Jilan Liu, M.D., M.H.A. Katherine M. Lombardo Gary McGlocklin Peter Miller, J.D. Susan Morgensztern Peggy Morrow Thomas ORourke Judy Pigott Gloria Pfeif Erick Rabins Thomas Ranken Chuck Robertson Gilbert Scherer Ezra Teshome Usha Varanasi, Ph.D. Tom Waldron Rick Weller, M.D., & H. Michelle A. Williams, Sc.D. Mary Williamson James Woods, Ph.D. Jeffrey Wortley Louis Yaseen

SENIOR SCIENTISTS
Peter Askovich, M.D., Ph.D. Jason Carnes, Ph.D. Amy DeRocher, Ph.D. Alan Diercks, Ph.D. Mark Gilchrist, Ph.D. Elizabeth Gold, M.D. Xuguang Hu, Ph.D. Heather Jaspan, Ph.D. Bryan Jensen, Ph.D. Kathleen Kennedy, Ph.D. Vladimir Litvak, Ph.D. Sebastian Mikolajczak, Ph.D. Brian Oliver, Ph.D. Stephen Ramsey, Ph.D. Carrie Rosenberger, Ph.D. Tige Rustad, Ph.D. Ramsey Saleem, Ph.D. Frank Schmitz, M.D., Ph.D. Shahin Shafiani, Ph.D. Ashley Vaughan, Ph.D. Daniel Zak, Ph.D.

AFFILIATE MEMBERS
Peter Doherty, MVSc, Ph.D. Patrick Duffy, M.D. Rob Moritz, Ph.D. Achim Schnaufer, Ph.D. Rentala Madhubala, Ph.D.

MANAGEMENT
Alan Aderem, Ph.D. Institute Director* Tom Blackwell, Director of Information Technology Karen Blchlinger, Ph.D. General Counsel Randy Hassler, Chief Operations Officer Kent Irwin, Director of Operations & Facilities Eileen Murphy, Senior Program Manager Kim Loveall Price, Interim Vice President of Advancement Lee Schoentrup, Director of Communications Ken Stuart, Ph.D. President & Founder** Jeanine Willis, Director of Human Resources Lynn Zimmerman, Director of Finance

Updated 10/2011

STAFF SCIENTISTS
Marion Avril, Ph.D. Samuel Danziger, Ph.D. Shokrollah Elahi, Ph.D. Shari Kaiser, Ph.D. Jiangning Li, Ph.D. Henning Mann, Ph.D. Aleksandr Ratushnyy, Ph.D. James Sissons, Ph.D. Vincent Tam, Ph.D.

BIOQUEST
Theresa Britschgi, Director of BioQuest

*Effective 1/12, President **Effective 1/12, President Emeritus & Founder

This is a publication of Seattle BioMeds Communications Department: Lee Schoentrup, director, and Jennifer Mortensen, specialist. Photo credits: Don Sodora, Ph.D., MaryMargaret Welch.

15

Lisa Meyr, Karen Blchlinger, Ph.D., and Kent Irwin

16

S E L E C T F I N A N C I A L D ATA
Fiscal years ending June 30 (dollars in thousands)

Revenue & support

Other income 7%

Budget by program area

Tuberculosis 11%

BOARD OF TR U S T E E S
Dean Allen Chief Executive Officer McKinstry Rosemary Barker Aragon Communications Advisory Group Chair Executive Director Pacific Hospital PDA Jane A. Biddle, Ph.D. Science Education Advisory Group Chair Technology Transfer Consultant Gregg Blodgett Community Volunteer Maud Daudon* Immediate Past Chair CEO & President Seattle-Northwest Securities Corporation Marlyn Friedlander Community Volunteer Jane Hedreen* Development Committee Co-Chair Owner, Flora & Henri Darryl Johnson* Secretary Former US Ambassador to Thailand & Lithuania Alan Levy, Ph.D. Venture Partner, Medical Devices Frazier Healthcare Ventures Neil McDonnell, PharmD Deputy Director of Strategy, Global Health Program Bill & Melinda Gates Foundation Terrence R. Meersman Vice President, Programs Margaret A Cargill Foundation Trevor Moody* Vice Chair President TM Strategic Advisors LLC Todd Patrick* Chair President & CEO C3-Jian, Inc. Christopher H. Porter, Ph.D. President Medical Genesis Kris Richey Development Committee Co-Chair Vice President Kinzer Real Estate Services Mike Stull* Treasurer & Finance Committee Chair Chief Financial Officer Clarisonic Moya Vazquez* Board Operations & Governance Committee Chair Community Volunteer Bryan White Managing Director & Chief Investment Officer BlackRock Alternative Advisors Melissa Yeager Chief Operating Officer Cardeas Pharma
*Executive Committee

Contributions 15% Government grants 54% Private Grants 24% HIV/AIDS 21%

Emerging & Neglected Diseases 35%

Malaria 33%

2011

2011

Statements of financial position

2011 Cash & investments Pledges receivable Other assets Property & equipment Total assets Accounts payable & accrued expenses Advances & deferred obligations Capital project debt Total liabilities Total net assets $21,203,046 $3,484,055 $7,683,610 $10,170,785 $42,541,496 $4,704,532 $10,335,651 $2,608,351 $17,648,534 $24,892,962 2010 $19,037,896 $432,449 $7,301,587 $10,934,896 $37,706,828 $4,593,542 $9,686,105 $3,481,384 $17,761,031 $19,945,797

Statements of activities
2011 Support & revenue Government grants Private grants Contributions Educational program Investment & other income Total support & revenue Expenses Research program Educational program Management & administrative Fundraising Total expenses Increase (decrease) in net assets $38,947,458 $869,233 $6,080,604 $845,270 $46,742,565 $4,947,165 $43,820,173 $933,110 $5,153,655 $811,036 $50,717,974 ($1,242,764) $27,858,893 $12,599,217 $7,737,172* $99,442 $3,395,006 $51,689,730 $23,723,086 $21,915,452 $494,903 $112,918 $3,228,851 $49,475,210 2010

*Includes one-time contribution to support scientific expansion and leadership Audited statements available upon request. Please e-mail connect@seattlebiomed.org.

17

18

2 0 11 DONOR HONOR R O L L

Hope starts with you.

It takes an incredible body of people to bring about the change in infectious diseases that an organization like Seattle BioMed is looking to make. Any person, in any professional discipline, has a contribution to give. Jill Scott, associate counsel for Seattle BioMed The people with the most influence on global health are people like you. You have invested your time and money, and you have joined us on our journey, to end the threat of infectious disease. Individuals, foundations and corporations that imagine a world free from this burden play a significant role in enabling Seattle BioMed to expand research programs, recruit innovative scientists and form powerful collaborations that will ultimately lead to a healthier world. We spread our hope through curiosity, inspiration and dedication, and we ask you to continue your investment in discovery research. Thank you for bringing us closer to our vision of a world free from infectious disease.

$2,500+
Anonymous (3) BNBuilders, Inc. Drs. Jane A. Biddle & Kenneth B. Seamon ClearPoint James & Sarah Davie Frazier Family Foundation GLY Construction Group Health Cooperative Betsy & Eric Hentz/Mallet Inc. Margot Kenly & Bill Cumming Life Technologies Moss Adams LLP Perkins+Will Gloria Pfeif Michael Podlin Christopher & Kathryn Porter Gordon & Gretchen Raine Redman Family Foundation Stephen Rothrock & Tessa Keating H. Jon & Judith Runstad Russell Investments Ronald & Sara Seubert Drs. Ken Stuart & Julie McElrath Daniel D. Syrdal Tommy Bahama Group VLST Corporation John & Teresa White Wilson Sonsini Goodrich & Rosati Melissa Yeager & Cory Van Arsdale ZymoGenetics, Inc.

Founders Circle $1,000,000+

Bill & Melinda Gates Foundation

$50,000+
Dean & Vicki Allen/McKinstry Co. Charitable Foundation Todd & Julie Patrick Silver Family Foundation

Becky Roberts Lucie Robitaille & Antoine Leblond Charles Spear Charitable Trust The Team Trio Fund in memory of Dr. David Clemetson Vulcan Inc. Wells Fargo Insurance Services We Work For Health

$25,000+
Anonymous Byron & Alice Lockwood Foundation Gilbert Scherer & Marlyn Friedlander

Pacesetters Circle $5,000+

Perry, Christine & Cooper Atkins Betty Bottler Concur Technologies, Inc. The Crowley Family Maud & Marc Daudon Firland Foundation Gilead Sciences, Inc. Richard & Elizabeth Hedreen Mike & Liz Hilton KeyBank National Association Kinzer Real Estate Services Lease Crutcher Lewis The Lucky Seven Foundation Mark Malamud & Susan Hautala Trevor J. Moody & Laura Hernon Petrizzo Bond, Inc. Kris Richey Moya Vazquez The Adam J. Weissman Foundation

$10,000+
Drs. Alan Aderem & Kathy Barker The Paul G. Allen Family Foundation Anonymous Gregg & Jane Blodgett The Crystal Family Foundation in memory of Norman S. Crystal Jane Hedreen & David Thyer KeyBank Foundation Jones Lang LaSalle

$1,000+
Bill & Janette Adamucci John & Leslie Aitchison Alexandria Real Estate Equities Inc. Lisa & Michael Anderson Rosemary Barker Aragon & Luis Aragon Mark Ashida & Lisbet Nilson The Baden Family Kristin & Steven Beaulieu Bruce & Ann Blume David & Madeleine Brenner Rich & Janice Bristol Victoria Buker Wayne & Jody Burns Randy Campadore

Clark Nuber P.S. Sally Collins & Chris Warth Paul & Debbie Cressman Steve Davis & Bob Evans Bruce Easter & Cynthia Faubion Deborah Elvins Nathan & Lisa Every Carolynn & Hal Ferris First Tech Credit Union JoAnn & Barry Forman Greg Foster Kerry Fowler & Jan Gray Malcolm J. Gardner & Ruobing Wang William & Mimi H. Gates, Sr. Kevin & Ann Harrang Hudson Bay Insulation Pam & Kim Kaiser R. Hans & Kelly Kemp ChiEun Kim Chris Larson & Julia Calhoun Alan & Sharon Levy Michael & Julie Metzger Morningside Foundation NBBJ Nyhus Communications PATH Jacques Peschon Mary Pigott Audi Purnaveja Wendy & Bill Rabel Erick & Marta Rabins & Family Pradip Rathod, Ph.D. The Reuben B. Robertson Foundation Lawrence J. Roseman Will & Lee Schoentrup Mike & Alex Shimizu Margaret & Hunt Stockwell Mike & Sandra Stull Ezra & Yobi Teshome Steven & Karen van Til John Wechkin & Erinn McIntyre Carl Weissman Mary Williamson & Kurt Kiefer Jeanine Willis & Eric Freyberg Tachi & Leslie Yamada Mariann & Kirk Zylstra Continued on page 21
20

19

2 0 11 DONOR HONOR R O L L

(continued)

Continued...

Supporters $500+
Eve & Chap Alvord Anonymous Sean Barnes Tracy Bennett Bonnie Berk Tom Blackwell Karen Blchlinger Anna Bran Robert & Theresa Britschgi Jayne Coe Beth & Marc Droppert Diane Dusseau Barbara Feasey & Bill Bryant Joe Fugere Saul & Devorah Gamoran Timothy S. Girvin & Dawn Clark Brad & Sarah Gray Joe W. & Denise Harris Randy & Melanie Hassler Steve & Amy Humphreys Kathlyn Huson Susan Hutchison Kent & Louise Irwin Darryl & Kathleen Johnson Maryann Jordan & Joe McDonnell Laird Norton Company LLC Susan Lammers & Walter Euyang Christina & Jim Lockwood McGraw-Hill Dorcas McLennan Glen & Alison Milliman Mortensen Family Fund Peter Myler & Alexa Allen Anthony Ogilvie Thomas ORiordan & Caroline Stamato Marilyn Parsons Dean Petterson Anne Pfeif Patricia Pfeif The Pew Charitable Trusts Sally Quy Regina Rabinovich & Franco Piazza Robert L. & Virginia R. Rausch

Jill Rosenast Scott & Kerry Rosenkranz Sabey Corporation Salal Credit Union Drs. Susan Scanlan & Anthony Lo Sidiya Schoppert Jill & Tristan Scott Seattle Seahawks & Seattle Sounders Joan Sedik Sellen Construction Genie Sheth Christine Simon Alan Smith & Christie Snyder Speckman Law Group Helen R. Stusser Sandhya Subramanian Ron & Hannah Tilden David & Lolly Victor The Doctors Whiteside Katherine & Richard Wolniewicz Marion Woodfield & Marc Weinberg Ann P. Wyckoff Jane Zalutsky & Mark Kantor

Nicole & Robert Mooney Alex & Nayla Morcos Eileen & Barry Murphy Joanie Parsons Cathy Perry David Powers & Amy Chasanov Udo & Carla Reich Maria K. Reyes Mike Schaefer Dr. Jaime Sepulveda Jennifer & Kirk Stephens Erik Strom Tim & Barbara Tasker Estelle N. Thyer Guy Thyer Toni & Michael Tibbits Kate Tune Nico Van der Meulen Joan Wright Eugene Yang

$250+
Benjamin O. Abe Susan Adler Bruce & Joann Amundson Tad & Cindy Anderson Robert S. Angel Anonymous (4) John & Linda Bowers Jeanne Brovold Evan Brown Igor Cestari Coleman Harris Julius Debro & Darlene Conley Jennifer Dodson Shannon Downey Nancy & Alan Emsley Quentin Ertel & Carolyn Kennedy Elaine Ervin Meredith & Steve Everist Rob Goldberg Diane Grover & Mark Kibbey Douglas Haas & Helena Hillinga-Haas M. Elizabeth Halloran Toni Hatzakis Frances Ann Hayes Hamilton Hazelhurst & Pam Bekins Ada Healey

$350
Jack & Sarah Aitchison Michelle Anderson & Paul Olivier Joe & Anne Baldwin Hallock Beals & Susan Carpenter Elisabeth Bodal Jerry Cangelosi & Gemma Borg Ken & Sharon Coleman Will & Ginelle Cousins Mark & Deb Davis Steve & Erin Eirschele Paul & Vanessa Faulkner Amy Haroon Ken & Cathi Hatch Tom & Sydney Hodge Helen Horton & Donald Carter Kate Joncas & David Traylor Karen Jones & Erik Rasmussen Craig & Danna Kinzer Marc & Charleen Kretschmer Peter & Melba Lancaster Neil & Merri Ann McDonnell

Scott & Emily Highleyman Karen M. Hill & Sheldon N. Rosen Bart Hoberecht Paul & Robin Holland Arthur E. Holtz Katy Horan & Dan Filonowich Mary Hu Lawton Humphrey Elizabeth James Stefan Kappe & Dasha Li Kappe Angela Kuo Alice Lin Jos Lopez, M.D. Minkyung & Marco Lowe Lisa & Nathaniel Meyr Sebastian Mikolajczak Nate Miles Tracy Mitchell Bruce & Joanne Montgomery, M.D. Ralph Munro David & Julie Park Judith Pierce John Pride Bridget Rafferty Kathleen Rydar Eric & Caroline Sanderson Rocky Sheldon & Ellen Fitzgerald Bryan Sherman Joseph & Leia Smith Marian Smith Don Sodora Otto H. Spoerl & Lyne Erving Michael Swift Carlos Trueba James Tucker David Tutt Drs. Kevin Urdahl & Maria Busch Tina Vlasaty Kimberly Vora & David Moxon Doug & Stacey Waddell Washington Biotechnology & Biomedical Association Katherine Weybright Ron Wilkowski & Kyla Fairchild Ann H. Williams Paul & Kathryn Wohnoutka Bernice Wuethrich Jon & Stephanie de Vaan

The 2011 donor list includes new pledges, outright gifts of cash and stock, pledge payments, and in-kind donations received from July 1, 2010, through June 30, 2011. Donors of $1,000 and above are listed on the donor wall at Seattle BioMed.

21

Each of our donors is important to us. Please e-mail connect@seattlebiomed.org with any omissions or errors.

Thank you for supporting us in our 35th anniversary year.

22

Hope starts with you.

Mission
Every day, we strive to eliminate the worlds most devastating infectious diseases.

Disease Focus
Emerging & Neglected Diseases African sleeping sickness Amebiasis Chagas disease Fungal infections Leishmaniasis Toxoplasmosis Malaria Tuberculosis Viral Diseases HIV/AIDS Influenza

Vision
We envision a world where people live free from the threat of infectious disease.

About Seattle BioMed

Seattle BioMed is the largest, independent, non-profit research institute in the U.S. focused solely on the worlds most devastating infectious diseases. More than 360 strong, we are dedicated to reducing human suffering and saving lives by converting knowledge into solutions. Our research is the foundation for new vaccines, drugs and diagnostics that will benefit those who need our help most: the 14 million who will otherwise die each year from infectious diseases.

On the cover: Ramsey Saleem, Ph.D., Crystal Dinh and Claire Gendrin, Ph.D.

307 Westlake Avenue North, Suite 500 Seattle, Washington 98109-5219 USA Phone: 206.256.7200 Fax: 206.256.7229 - seattlebiomed.org Seattle Biomedical Research Institute is a 501(c)3 nonprofit organization. Federal tax ID #91-0961784.
2011 Seattle Biomedical Research Institute. Printed on recycled paper.